Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

By R. Burger, M. Sill, B. Monk, B. Greer, J. Sorosky. Journal of Clinical Oncology, 2007

914 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Curcumin and cancer: an "old-age" disease with an "age-old" solution. (2008, background): “This has been attributed largely to limitations in cytotoxic therapy, including intrinsic and acquired drug resistance and the lack of specificity of agents targeting mechanisms of disease progression [132].”
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. (2011, methodology): “The GOG (Gynecologic Oncology Group) 170D study evaluated single-agent BV at 15 mg/kg every 3 weeks in 62 patients who had received one to two prior regimens.(7) The objective response rate (ORR) was 21% (90% CI, 12.”
Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, background): “gle agent in patients with 1 or 2 prior therapies who had recurred within 12 months of treatment with a platinum agent.(111) This phase 2 study demonstrated an overall response rate of 21%, with 52% of patients having stable disease as their best response and 40%”